0000000000677592

AUTHOR

V. Brescia Morra

showing 3 related works from this author

Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study

2009

Background To investigate in a large cohort of patients with multiple sclerosis (MS), lesion load and atrophy evolution, and the relationship between clinical and magnetic resonance imaging (MRI) correlates of disease progression. Methods Two hundred and sixty-seven patients with MS were studied at baseline and two years later using the same MRI protocol. Abnormal white matter fraction, normal appearing white matter fraction, global white matter fraction, gray matter fraction and whole brain fraction, T2-hyperintense, and T1-hypointense lesions were measured at both time points. Results The majority of patients were clinically stable, whereas MRI-derived brain tissue fractions were signifi…

AdultMalePathologymedicine.medical_specialtyAdolescentCentral nervous systemmultiple sclerosisSeverity of Illness IndexLesion loadWhite matterCentral nervous system diseaseYoung AdultDegenerative diseaseAtrophyMultiple Sclerosis Relapsing-RemittingatrophyRisk FactorsT2 lesionsmedicinefollow upHumansAgedmedicine.diagnostic_testbusiness.industryMultiple sclerosisBrain AtrophyBrainMagnetic resonance imagingMiddle AgedMultiple Sclerosis Chronic Progressivelesion loadmedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structureCross-Sectional StudiesLogistic ModelsNeurologymultiple sclerosiMultivariate AnalysisDisease ProgressionFemaleSettore MED/26 - NeurologiaNeurology (clinical)businessFollow-Up StudiesMRI
researchProduct

Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors

2021

Background: No uniform criteria for a sensitive identification of the transition from relapsing–remitting multiple sclerosis (MS) to secondary-progressive multiple sclerosis (SPMS) are available. Objective: To compare risk factors of SPMS using two definitions: one based on the neurologist judgment (ND) and an objective data-driven algorithm (DDA). Methods: Relapsing-onset MS patients ( n = 19,318) were extracted from the Italian MS Registry. Risk factors for SPMS and for reaching irreversible Expanded Disability Status Scale (EDSS) 6.0, after SP transition, were estimated using multivariable Cox regression models. Results: SPMS identified by the DDA ( n = 2343, 12.1%) were older, more disa…

Oncologymedicine.medical_specialtyRelapsing-RemittingMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineDisease registryRecurrenceRisk Factorsbig dataInternal medicinemedicineHumansdata-driven algorithmMultiple sclerosi030212 general & internal medicinebig data; data-driven algorithm; disease registry; Multiple sclerosis; prognosis; secondary progressive; Disease Progression; Humans; Recurrence; Risk Factors; Multiple Sclerosis; Multiple Sclerosis Chronic Progressive; Multiple Sclerosis Relapsing-RemittingSecondary progressiveTransition (genetics)business.industryMultiple sclerosisMultiple Sclerosis Chronic Progressivemedicine.diseaseChronic ProgressiveNeurologybig data; data-driven algorithm; disease registry; Multiple sclerosis; prognosis; secondary progressiveDisease Progressiondisease registrysecondary progressiveSettore MED/26 - NeurologiaNeurology (clinical)prognosisbusinessprognosi030217 neurology & neurosurgery
researchProduct

Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon bet…

2011

Background: The precise relationships among quality of life, depression, fatigue and cognitive impairment in multiple sclerosis (MS) are complex and poorly understood. Objective: To assess the effects of subcutaneous interferon beta-1a on quality of life, depression and fatigue over 3 years in the COGIMUS study, and to examine the relationship between these outcomes and baseline cognitive status. Methods: COGIMUS was an observational 3-year trial assessing cognitive function in 459 patients with relapsing–remitting MS treated with subcutaneous interferon beta-1a. Results: In total, 331 patients completed the study (168 received interferon beta-1a, 44 µg subcutaneously three times weekly, a…

AdultMaleQuality of lifeLongitudinal studymedicine.medical_specialtyInjections Subcutaneousmultiple sclerosisRelapsing-Remitting Multiple SclerosisInterferon beta 1aYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicQuality of lifeInternal medicinemedicineHumansYoung adultFatigueDepression (differential diagnoses)AgedDepressionbusiness.industryCognitive function; Depression; Fatigue; Interferon beta 1a; Longitudinal study; Quality of life; Relapsing-Remitting Multiple SclerosisMultiple sclerosisCognitive disorderInterferon beta-1aInterferon-betaMiddle Agedmedicine.diseaseClinical trialNeurologyPhysical therapymultiple sclerosis cognition interferon betaFemaleSettore MED/26 - NeurologiaCognitive functionNeurology (clinical)Longitudinal studyCognition DisordersbusinessInterferon beta-1amedicine.drugMultiple Sclerosis Journal
researchProduct